Edition:
United States

Sunesis Pharmaceuticals Inc (SNSS.OQ)

SNSS.OQ on NASDAQ Stock Exchange Capital Market

3.33USD
3:59pm EST
Change (% chg)

$-0.11 (-3.20%)
Prev Close
$3.44
Open
$3.48
Day's High
$3.50
Day's Low
$3.21
Volume
120,332
Avg. Vol
30,674
52-wk High
$4.44
52-wk Low
$1.84

Latest Key Developments (Source: Significant Developments)

Sunesis Pharmaceuticals Inc - Daniel Swisher Resigns As CEO Effective End Of 2017
Monday, 4 Dec 2017 04:05pm EST 

Dec 4 (Reuters) - Sunesis Pharmaceuticals Inc ::SUNESIS PHARMACEUTICALS INC - DANIEL SWISHER RESIGNS AS CEO EFFECTIVE END OF 2017.SUNESIS PHARMACEUTICALS INC - SWISHER TO REMAIN WITH SUNESIS AS A STRATEGIC ADVISOR.SUNESIS PHARMACEUTICALS INC - BOARD MEMBER DAYTON MISFELDT APPOINTED INTERIM CEO EFFECTIVE JANUARY 2018.  Full Article

Sunesis Pharmaceuticals Appoints William Quinn As CFO
Thursday, 30 Nov 2017 07:00am EST 

Nov 30 (Reuters) - Sunesis Pharmaceuticals Inc ::SUNESIS PHARMACEUTICALS APPOINTS WILLIAM QUINN AS CHIEF FINANCIAL OFFICER AND SENIOR VICE PRESIDENT, FINANCE AND CORPORATE DEVELOPMENT.SUNESIS PHARMACEUTICALS INC - ‍WILLIAM QUINN MOST RECENTLY SERVING AS CEO AND CO-FOUNDER OF PRIVATE CANCER IMMUNOTHERAPY COMPANY BULLET BIOTECHNOLOGY​.  Full Article

Sunesis Pharmaceuticals Inc Q3 loss per share ‍$0.43​
Thursday, 2 Nov 2017 07:00am EDT 

Nov 2 (Reuters) - Sunesis Pharmaceuticals Inc :Sunesis Pharmaceuticals reports third quarter 2017 financial results and recent highlights.Sunesis Pharmaceuticals Inc qtrly loss per share ‍$0.43​.Sunesis Pharmaceuticals Inc- ‍pro-forma Sept 30, 2017 cash, cash equivalents and marketable securities of $37.1 million is expected to fund co into 2019​.  Full Article

Sunesis announces pricing of $20 million offering of securities
Wednesday, 25 Oct 2017 08:54am EDT 

Oct 25 (Reuters) - Sunesis Pharmaceuticals Inc ::Sunesis announces pricing of $20 million offering of securities.Sunesis Pharmaceuticals Inc - pricing of underwritten public offerings of 7.5 million shares and accompanying warrants to purchase 3.8 million shares​.Sunesis Pharmaceuticals- ‍also priced 2,500 shares of non-voting series D convertible preferred stock, accompanying warrants to purchase 1.3 million shares​.  Full Article

Sunesis Pharmaceuticals announces proposed public offering of common stock, preferred stock and warrants
Tuesday, 24 Oct 2017 04:05pm EDT 

Oct 25 (Reuters) - Sunesis Pharmaceuticals Inc :Sunesis announces proposed public offering of common stock, preferred stock and warrants.Sunesis Pharmaceuticals Inc - ‍anticipates using net proceeds from proposed offerings to fund development of sns-062, additional kinase inhibitor programs​.  Full Article

Sunesis Pharmaceuticals reports second quarter results
Thursday, 27 Jul 2017 07:00am EDT 

July 27 (Reuters) - Sunesis Pharmaceuticals Inc :Sunesis Pharmaceuticals reports second quarter 2017 financial results and recent highlights.Says loss from operations for three months ended June 30, 2017 was $8.6 million.Says as of June 30, 2017, cash, cash equivalents and marketable securities totaled $22.7 million..  Full Article

Balyasny Asset Management reports 9.32 pct passive stake in Sunesis Pharmaceuticals
Wednesday, 5 Jul 2017 02:29pm EDT 

July 5 (Reuters) - Balyasny Asset Management::Balyasny Asset Management reports a 9.32 percent passive stake in Sunesis Pharmaceuticals Inc as of June 23, 2017 - SEC filing.  Full Article

Sunesis Pharmaceuticals amends loan agreement
Friday, 30 Jun 2017 05:05pm EDT 

June 30 (Reuters) - Sunesis Pharmaceuticals Inc :Sunesis Pharmaceuticals Inc - on June 30, 2017, co entered into an amendment, or amendment, to loan and security agreement dated march 31, 2016.Sunesis Pharmaceuticals Inc - amendment modifies loan repayment terms to be interest-only through july 1, 2018.  Full Article

Sunesis Pharmaceuticals files for mixed shelf of up to $200 mln
Thursday, 8 Jun 2017 04:51pm EDT 

June 8 (Reuters) - Sunesis Pharmaceuticals Inc :Files for mixed shelf of up to $200 million - SEC filing.  Full Article

Sunesis Pharmaceuticals qtrly basic and diluted loss per share $0.47
Monday, 8 May 2017 07:00am EDT 

May 8 (Reuters) - Sunesis Pharmaceuticals Inc :Sunesis pharmaceuticals reports first quarter 2017 financial results and recent highlights.Q1 revenue $700,000 versus $600,000.Q1 revenue view $1.6 million -- Thomson Reuters I/B/E/S.Sunesis pharmaceuticals inc qtrly basic and diluted loss per share of $0.47.Q1 earnings per share view $-0.69 -- Thomson Reuters I/B/E/S.Sunesis pharmaceuticals inc - expects that its current cash resources are sufficient to fund company into june 2018.  Full Article